New drug combo may let CML patients pause treatment
NCT ID NCT04070443
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether starting with a stronger drug (ponatinib) for 6 months, then switching to a standard drug (imatinib) for at least 30 months, can help adults with newly diagnosed chronic myeloid leukemia reach deep remission. The goal is to see if patients can then safely stop all treatment. About 170 people aged 18 to 65 are taking part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ponatinib and imatinib (drugs)
- What this could lead to
- If successful, this approach could allow some patients with chronic myeloid leukemia to stop treatment and stay in remission for years.
- What could go wrong
- This is a mid-stage trial with 170 participants, so results are not final. Ponatinib can cause serious side effects like blood clots or heart problems, and not everyone may achieve stable remission.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BCR-ABL POSITIVE CHRONIC MYELOGENOUS LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CH d'Avignon
Avignon, 84000, France
-
CH de Versailles - Hôpital André Mignot
Le Chesnay, France
-
CHRU Nancy/Brabois
Vandœuvre-lès-Nancy, 54500, France
-
CHU Limoges - Hôpital Dupuytren
Limoges, France
-
CHU Nîmes Caremeau - Institut de Cancérologie du Gard
Nîmes, France
-
CHU Strasbourg
Strasbourg, 67000, France
-
CHU d'Angers
Angers, France
-
CHU de Grenoble
Grenoble, 38000, France
-
Centre Hospitalier Annecy-Genevois
Annecy, 74000, France
-
Centre Hospitalier Sud Francilien
Corbeil-Essonnes, 91000, France
-
Centre Léon Bérard
Lyon, 69008, France
-
Chru Besançon
Besançon, 25000, France
-
Chru Brest
Brest, France
-
Chu - Hopital de Pontchaillou
Rennes, 35000, France
-
Chu Amiens Picardie
Amiens, 80000, France
-
Chu D'Estaing
Clermont-Ferrand, 63000, France
-
Chu Hotel Dieu
Nantes, 44000, France
-
Chu Poitiers
Poitiers, France
-
Hopital Henri Mondor
Créteil, 94000, France
-
Hopital Paul Brousse
Villejuif, 94800, France
-
Hopital Saint Eloi
Montpellier, 34000, France
-
Hopital Saintantoine
Paris, 75000, France
-
Hôpital Claude Huriez - CHRU de Lille
Lille, France
-
Institut Bergonie
Bordeaux, 33000, France
-
Institut D'Hematologie de Basse Normandie
Caen, 14000, France
-
Institut Paoli Calmettes
Marseille, 13000, France
-
Institut de Cancérologie Lucien Neuwirth
Saint-Priest-en-Jarez, France
-
Iuct Toulouse - Oncopole
Toulouse, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.